{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:36:58Z","timestamp":1789677418092,"version":"4.0.1"},"reference-count":108,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300675"],"award-info":[{"award-number":["82300675"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["824B2088"],"award-info":[{"award-number":["824B2088"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32470757"],"award-info":[{"award-number":["32470757"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016359","name":"Zhongnan Hospital of Wuhan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007046","name":"Wuhan University","doi-asserted-by":"publisher","award":["ZLYNXM202004"],"award-info":[{"award-number":["ZLYNXM202004"]}],"id":[{"id":"10.13039\/501100007046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007046","name":"Wuhan University","doi-asserted-by":"publisher","award":["PTXM2023008"],"award-info":[{"award-number":["PTXM2023008"]}],"id":[{"id":"10.13039\/501100007046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.tem.2025.06.008","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:08:12Z","timestamp":1753099692000},"page":"262-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Metabolic-immune microenvironment crosstalk mediating ICI resistance in MASH-HCC"],"prefix":"10.1016","volume":"37","author":[{"given":"Yi","family":"Ju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kequan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiangen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2025.06.008_bb0005","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","article-title":"Molecular pathogenesis and systemic therapies for hepatocellular carcinoma","volume":"3","author":"Llovet","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.tem.2025.06.008_bb0010","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jhep.2024.07.017","article-title":"Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"82","author":"Lau","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.06.008_bb0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tem.2025.06.008_bb0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tem.2025.06.008_bb0025","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2025.06.008_bb0030","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1053\/j.gastro.2021.06.008","article-title":"Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002-2020)","volume":"161","author":"Haber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tem.2025.06.008_bb0035","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.tem.2025.06.008_bb0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, Phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tem.2025.06.008_bb0045","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jhep.2020.08.010","article-title":"Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma","volume":"74","author":"Kim","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.06.008_bb0050","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S2468-1253(23)00454-5","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised Phase 3 study","volume":"9","author":"Yau","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2025.06.008_bb0055","article-title":"Pan-viral serology uncovers distinct virome patterns as risk predictors of hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"4","author":"Do","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.tem.2025.06.008_bb0060","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/HEP.0000000000000591","article-title":"Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma","volume":"79","author":"Li","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2025.06.008_bb0065","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tem.2025.06.008_bb0070","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1038\/s41591-024-03240-y","article-title":"Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab","volume":"30","author":"Alban","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.tem.2025.06.008_bb0075","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1136\/gutjnl-2023-331117","article-title":"Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma","volume":"73","author":"Wen","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.tem.2025.06.008_bb0080","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300706120","article-title":"Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells","volume":"120","author":"Gu","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tem.2025.06.008_bb0085","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1074\/jbc.RA120.012730","article-title":"Deletion of fatty acid transport protein 2 (FATP2) in the mouse liver changes the metabolic landscape by increasing the expression of PPAR\u03b1-regulated genes","volume":"295","author":"Perez","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tem.2025.06.008_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101428","article-title":"CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing","volume":"57","author":"Zeng","year":"2022","journal-title":"Mol. Metab."},{"key":"10.1016\/j.tem.2025.06.008_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115246","article-title":"Meteorin-like alleviates hepatic steatosis by regulating hepatic triglyceride secretion and fatty acid oxidation","volume":"44","author":"Song","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.tem.2025.06.008_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117510","article-title":"Morusin, a novel inhibitor of ACLY, induces mitochondrial apoptosis in hepatocellular carcinoma cells through ROS-mediated mitophagy","volume":"180","author":"Li","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tem.2025.06.008_bb0105","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2024.02.009","article-title":"Acetyl-CoA carboxylase obstructs CD8(+) T cell lipid utilization in the tumor microenvironment","volume":"36","author":"Hunt","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.tem.2025.06.008_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.696961","article-title":"Targeting fatty acid synthase modulates metabolic pathways and inhibits cholangiocarcinoma cell progression","volume":"12","author":"Tomacha","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tem.2025.06.008_bb0115","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s41467-024-45548-w","article-title":"The transcription factor ChREBP orchestrates liver carcinogenesis by coordinating the PI3K\/AKT signaling and cancer metabolism","volume":"15","author":"Benichou","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tem.2025.06.008_bb0120","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70006","article-title":"Simultaneous activation of beta-oxidation and de novo lipogenesis in MASLD-HCC: a new paradigm","volume":"45","author":"Dahboul","year":"2025","journal-title":"Liver Int."},{"key":"10.1016\/j.tem.2025.06.008_bb0125","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/gutjnl-2018-317581","article-title":"Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans","volume":"69","author":"Che","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.tem.2025.06.008_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114962","article-title":"ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma","volume":"43","author":"Wu","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.tem.2025.06.008_bb0135","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000606","article-title":"High-fat\/high-sucrose diet results in a high rate of MASH with HCC in a mouse model of human-like bile acid composition","volume":"9","author":"Ueda","year":"2025","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.tem.2025.06.008_bb0140","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2022.5407","article-title":"Hepatocellular carcinoma: novel understandings and therapeutic strategies based on bile acids (review)","volume":"61","author":"Luo","year":"2022","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.tem.2025.06.008_bb0145","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1038\/s41467-025-58809-z","article-title":"Disrupting bile acid metabolism by suppressing Fxr causes hepatocellular carcinoma induced by YAP activation","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tem.2025.06.008_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106261","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: from molecular mechanisms to potential clinical implications","volume":"181","author":"Arvanitakis","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tem.2025.06.008_bb0155","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41586-024-08317-9","article-title":"FBP1 controls liver cancer evolution from senescent MASH hepatocytes","volume":"637","author":"Gu","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.tem.2025.06.008_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108487","article-title":"HCAR1\/MCT1 regulates tumor ferroptosis through the lactate-mediated AMPK-SCD1 activity and its therapeutic implications","volume":"33","author":"Zhao","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.tem.2025.06.008_bb0165","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1038\/s41388-023-02757-9","article-title":"A positive feedback between cholesterol synthesis and the pentose phosphate pathway rather than glycolysis promotes hepatocellular carcinoma","volume":"42","author":"Hu","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.tem.2025.06.008_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1344971","article-title":"Hypoxia-inducible factor-2\u03b1 promotes fibrosis in non-alcoholic fatty liver disease by enhancing glutamine catabolism and inhibiting yes-associated protein phosphorylation in hepatic stellate cells","volume":"15","author":"Yan","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.tem.2025.06.008_bb0175","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/s41467-021-21804-1","article-title":"Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma","volume":"12","author":"Hung","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tem.2025.06.008_bb0180","doi-asserted-by":"crossref","first-page":"79","DOI":"10.17998\/jlc.2024.12.27","article-title":"Synergistic effects of L-arginine and argininosuccinate synthetase 1 in inducing apoptosis in hepatocellular carcinoma","volume":"25","author":"Kim","year":"2025","journal-title":"J. Liver Cancer"},{"key":"10.1016\/j.tem.2025.06.008_bb0185","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2024.09.029","article-title":"FABP5(+) lipid-loaded macrophages process tumour-derived unsaturated fatty acid signal to suppress T-cell antitumour immunity","volume":"82","author":"Yang","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.06.008_bb0190","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20241442","article-title":"Tumor-associated neutrophils attenuate the immunosensitivity of hepatocellular carcinoma","volume":"222","author":"Teo","year":"2025","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tem.2025.06.008_bb0195","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.ccell.2023.04.016","article-title":"Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity","volume":"41","author":"Yan","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tem.2025.06.008_bb0200","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1053\/j.gastro.2020.01.028","article-title":"High serum levels of cholesterol increase antitumor functions of nature killer cells and reduce growth of liver tumors in mice","volume":"158","author":"Qin","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tem.2025.06.008_bb0205","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41467-020-14332-x","article-title":"Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cells","volume":"11","author":"Fu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tem.2025.06.008_bb0210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hep.32348","article-title":"Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack","volume":"77","author":"Fang","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2025.06.008_bb0215","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41586-023-06409-6","article-title":"Lactate limits CNS autoimmunity by stabilizing HIF-1\u03b1 in dendritic cells","volume":"620","author":"Sanmarco","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.tem.2025.06.008_bb0220","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41590-024-02068-5","article-title":"The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer","volume":"26","author":"He","year":"2025","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tem.2025.06.008_bb0225","doi-asserted-by":"crossref","DOI":"10.1084\/jem.2021004202072022c","article-title":"Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function","volume":"219","author":"Dyck","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tem.2025.06.008_bb0230","doi-asserted-by":"crossref","DOI":"10.1172\/JCI161713","article-title":"Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression","volume":"133","author":"Gou","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2025.06.008_bb0235","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s42255-024-01019-6","article-title":"Fatty acid binding protein 5 suppression attenuates obesity-induced hepatocellular carcinoma by promoting ferroptosis and intratumoral immune rewiring","volume":"6","author":"Sun","year":"2024","journal-title":"Nat. Metab."},{"key":"10.1016\/j.tem.2025.06.008_bb0240","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41577-024-01087-5","article-title":"How oxygenation shapes immune responses: emerging roles for physioxia and pathological hypoxia","volume":"25","author":"Mirchandani","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tem.2025.06.008_bb0245","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tem.2025.06.008_bb0250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1158\/0008-5472.CAN-24-2324","article-title":"HIF1\u03b1 counteracts TGF\u03b21-driven TSP1 expression in endothelial cells to stimulate angiogenesis in the hypoxic tumor microenvironment","volume":"85","author":"Luo","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.tem.2025.06.008_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411546","article-title":"Suppression of NASH-related HCC by farnesyltransferase inhibitor through inhibition of inflammation and hypoxia-inducible factor-1\u03b1 expression","volume":"24","author":"Yamada","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tem.2025.06.008_bb0260","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011648","article-title":"FMO2(+) cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma","volume":"13","author":"Xu","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tem.2025.06.008_bb0265","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001386","article-title":"Hepatic stellate cell heterogeneity: functional aspects and therapeutic implications","author":"Geng","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2025.06.008_bb0270","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41586-022-05289-6","article-title":"Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis","volume":"610","author":"Filliol","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.tem.2025.06.008_bb0275","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2147\/OTT.S234920","article-title":"Activated hepatic stellate cells (HSCs) exert immunosuppressive effects in hepatocellular carcinoma by producing complement C3","volume":"13","author":"Xu","year":"2020","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.tem.2025.06.008_bb0280","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12964-025-02162-7","article-title":"LAMA4(+) CD90(+) eCAFs provide immunosuppressive microenvironment for liver cancer through induction of CD8(+) T cell senescence","volume":"23","author":"Zhang","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.tem.2025.06.008_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2024.113947","article-title":"Cancer-associated fibroblasts contributed to hepatocellular carcinoma recurrence and metastasis via CD36-mediated fatty-acid metabolic reprogramming","volume":"435","author":"Wang","year":"2024","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.tem.2025.06.008_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113773","article-title":"THBS1(+) myeloid cells expand in SLD hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through TREM1","volume":"43","author":"Giraud","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.tem.2025.06.008_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108114","article-title":"Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy","volume":"235","author":"Joshi","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tem.2025.06.008_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114254","article-title":"Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-\u03b3\/NSDHL\/SREBP1\/TGF-\u03b21 axis in hepatocellular carcinoma","volume":"159","author":"Xie","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tem.2025.06.008_bb0305","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","article-title":"Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma","volume":"12","author":"Behary","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tem.2025.06.008_bb0310","article-title":"Dynamic changes of gut microbiota in mouse models of metabolic dysfunction-associated steatohepatitis and its transition to hepatocellular carcinoma","volume":"38","author":"Wang","year":"2024","journal-title":"FASEB J."},{"key":"10.1016\/j.tem.2025.06.008_bb0315","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1038\/s41467-022-31312-5","article-title":"Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment","volume":"13","author":"Schneider","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tem.2025.06.008_bb0320","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.3390\/ijms25084405","article-title":"Role of epiregulin on lipopolysaccharide-induced hepatocarcinogenesis as a mediator via EGFR signaling in the cancer microenvironment","volume":"25","author":"Kubo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tem.2025.06.008_bb0325","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.3390\/medicina59122191","article-title":"Diagnostic and prognostic value of IL-10, FABP2 and LPS levels in HCC patients","volume":"59","author":"Morkunas","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.tem.2025.06.008_bb0330","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2392864","article-title":"Changes in intestinal permeability and gut microbiota following diet-induced weight loss in patients with metabolic dysfunction-associated steatohepatitis and liver fibrosis","volume":"16","author":"Koutoukidis","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.tem.2025.06.008_bb0335","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.neo.2021.04.004","article-title":"Short chain fatty acids delay the development of hepatocellular carcinoma in HBx transgenic mice","volume":"23","author":"McBrearty","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.tem.2025.06.008_bb0340","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jhep.2022.02.030","article-title":"Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis","volume":"77","author":"Sun","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.06.008_bb0345","article-title":"The intrahepatic bacterial metataxonomic signature of patients with hepatocellular carcinoma","volume":"14","author":"Li","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tem.2025.06.008_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413510","article-title":"Etiology-dependent microbiome differences in hepatocellular carcinoma development","volume":"25","author":"Todorovic","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tem.2025.06.008_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29485","article-title":"Hepatitis B virus-related hepatocellular carcinoma exhibits distinct intratumoral microbiota and immune microenvironment signatures","volume":"96","author":"Liu","year":"2024","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.tem.2025.06.008_bb0360","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1016\/j.cell.2022.09.005","article-title":"Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions","volume":"185","author":"Narunsky-Haziza","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.tem.2025.06.008_bb0365","article-title":"Tumor-resident Malassezia can promote hepatocellular carcinoma development by downregulating bile acid synthesis and modulating tumor microenvironment","volume":"15","author":"Shen","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tem.2025.06.008_bb0370","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","article-title":"Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia","volume":"34","author":"Morrow","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.tem.2025.06.008_bb0375","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jcmgh.2020.06.001","article-title":"Acetyl-CoA carboxylase inhibition improves multiple dimensions of NASH pathogenesis in model systems","volume":"10","author":"Ross","year":"2020","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2025.06.008_bb0380","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/0008-5472.CAN-23-0966","article-title":"FASN inhibition decreases MHC-I degradation and synergizes with PD-L1 checkpoint blockade in hepatocellular carcinoma","volume":"84","author":"Huang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.tem.2025.06.008_bb0385","article-title":"METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy","volume":"4","author":"Pan","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.tem.2025.06.008_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108503","article-title":"Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation","volume":"104","author":"Hazem","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.tem.2025.06.008_bb0395","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153110","article-title":"Carbonic anhydrase XII mediates the survival and prometastatic functions of macrophages in human hepatocellular carcinoma","volume":"132","author":"Ning","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2025.06.008_bb0400","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2025.06.008_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2021.1875774","article-title":"Effects of colon-targeted vitamins on the composition and metabolic activity of the human gut microbiome- a pilot study","volume":"13","author":"Pham","year":"2021","journal-title":"Gut Microbes"},{"key":"10.1016\/j.tem.2025.06.008_bb0410","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000829","article-title":"Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a Phase II trial","volume":"8","author":"Zamarin","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tem.2025.06.008_bb0415","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1158\/2159-8290.CD-21-0900","article-title":"Vitamin E enhances cancer immunotherapy by reinvigorating dendritic cells via targeting checkpoint SHP1","volume":"12","author":"Yuan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tem.2025.06.008_bb0420","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jhep.2022.03.010","article-title":"Metformin treatment rescues CD8(+) T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD","volume":"77","author":"Wabitsch","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.06.008_bb0425","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado9311","article-title":"Compromised macrophages contribute to progression of MASH to hepatocellular carcinoma in FGF21KO mice","volume":"10","author":"Shi","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tem.2025.06.008_bb0430","article-title":"Efficacy comparison of immune combination therapies in subgroups for advanced hepatocellular carcinoma patients: systematic review and network meta-analysis","volume":"19","author":"Wang","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.tem.2025.06.008_bb0435","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41388-020-01636-x","article-title":"HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.tem.2025.06.008_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.626663","article-title":"Construction of novel lncRNA-miRNA-mRNA network associated with recurrence and identification of immune-related potential regulatory axis in hepatocellular carcinoma","volume":"11","author":"Zhan","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tem.2025.06.008_bb0445","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-020-01213-6","article-title":"Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p\/snail\/DPP4 axis","volume":"19","author":"Huang","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tem.2025.06.008_bb0450","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.tem.2025.06.008_bb0455","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12885-023-10530-0","article-title":"Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL\/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet","volume":"23","author":"Giri","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tem.2025.06.008_bb0460","first-page":"S46","article-title":"Treatment of nonalcoholic steatohepatitis by obeticholic acid: current status","volume":"12","author":"Roy","year":"2022","journal-title":"Euroasian J. Hepatogastroenterol."},{"key":"10.1016\/j.tem.2025.06.008_bb0465","article-title":"Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma","volume":"6","author":"Wu","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.tem.2025.06.008_bb0470","doi-asserted-by":"crossref","first-page":"327","DOI":"10.31083\/j.fbl2812327","article-title":"Quercetin\/anti-PD-1 antibody combination therapy regulates the gut microbiota, impacts macrophage immunity and reshapes the hepatocellular carcinoma tumor microenvironment","volume":"28","author":"Wu","year":"2023","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"10.1016\/j.tem.2025.06.008_bb0475","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial","volume":"12","author":"Xue","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.tem.2025.06.008_bb0480","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.chom.2024.06.010","article-title":"Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor","volume":"32","author":"Kim","year":"2024","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.tem.2025.06.008_bb0485","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41586-021-04003-2","article-title":"Metabolic modulation of tumours with engineered bacteria for immunotherapy","volume":"598","author":"Canale","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.tem.2025.06.008_bb0490","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jhep.2023.02.033","article-title":"Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation","volume":"79","author":"Yahoo","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.06.008_bb0495","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwad167","article-title":"Proteomics of adjacent-to-tumor samples uncovers clinically relevant biological events in hepatocellular carcinoma","volume":"10","author":"Zhu","year":"2023","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.tem.2025.06.008_bb0500","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmet.2024.10.008","article-title":"A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis","volume":"37","author":"Zhang","year":"2025","journal-title":"Cell Metab."},{"key":"10.1016\/j.tem.2025.06.008_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156063","article-title":"Serum lipidomic signatures in patients with varying histological severity of metabolic-dysfunction associated steatotic liver disease","volume":"162","author":"Muralidharan","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.tem.2025.06.008_bb0510","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2025.06.008_bb0515","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2025.06.008_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2022.100925","article-title":"Preclinical models of non-alcoholic steatohepatitis leading to hepatocellular carcinoma","volume":"87","author":"Green","year":"2023","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.tem.2025.06.008_bb0525","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s42255-022-00700-y","article-title":"A researcher's guide to preclinical mouse NASH models","volume":"4","author":"Gallage","year":"2022","journal-title":"Nat. Metab."},{"key":"10.1016\/j.tem.2025.06.008_bb0530","doi-asserted-by":"crossref","first-page":"593","DOI":"10.33549\/physiolres.935237","article-title":"Western diet-induced nonalcoholic fatty liver disease mice mimic the key transcriptomic signatures observed in humans","volume":"73","author":"Ishigure","year":"2024","journal-title":"Physiol. Res."},{"key":"10.1016\/j.tem.2025.06.008_bb0535","doi-asserted-by":"crossref","first-page":"551","DOI":"10.24272\/j.issn.2095-8137.2024.002","article-title":"Overexpression of wild-type HRAS drives non-alcoholic steatohepatitis to hepatocellular carcinoma in mice","volume":"45","author":"Ling","year":"2024","journal-title":"Zool. Res."},{"key":"10.1016\/j.tem.2025.06.008_bb0540","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.31000","article-title":"Fatty acid synthase inhibitor TVB-2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities","volume":"72","author":"Syed-Abdul","year":"2020","journal-title":"Hepatology"}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276025001468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276025001468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:28:35Z","timestamp":1778581715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276025001468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1043276025001468"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2025.06.008","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic-immune microenvironment crosstalk mediating ICI resistance in MASH-HCC","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2025.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}